Abstract
Summary
The Diabetes Partnering 2007-2012 report provides understanding and access to
the diabetes partnering deals and agreements entered into by the worlds
leading healthcare companies.
- Trends in diabetes partnering deals
- Top diabetes deals by value
- Deals listed by company A-Z, industry sector, stage of development,
technology type
Description
The Diabetes Partnering 2007-2012 provides understanding and access to
the diabetes partnering deals and agreements entered into by the worlds
leading healthcare companies.
The report provides an analysis of diabetes partnering deals. The majority of
deals are discovery or development stage whereby the licensee obtains a
right or an option right to license the licensors diabetes technology. These
deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This data driven report contains over 500 links to online copies of actual
diabetes deals and contract documents as submitted to the Securities Exchange
Commission by companies and their partners, where available. Contract
documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which will
have a significant impact on each party's ability to derive value from the
deal.
The initial chapters of this report provide an orientation of diabetes
partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an
overview of the trends in diabetes partnering since 2007, including a summary
of deals by industry sector, stage of development, deal type, and technology
type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading diabetes deals since 2007. Deals
are listed by headline value, signed by bigpharma, most active bigpharma.
Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 4 provides a comprehensive directory of diabetes partnering deals
signed and announced since 2007. The chapter is organized by company A-Z,
stage of development at signing, deal type (collaborative R&D,
co-promotion, licensing etc), and technology type. Each deal title
links via Weblink to an online version of the deal record, and where available
the contract document, providing easy access to each contract document on
demand.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
diabetes technologies and products.
Report scope
Diabetes Partnering 2007-2012 is intended to provide the reader with an
in-depth understanding and access to diabetes trends and structure of deals
entered into by leading companies worldwide.
This data driven report includes:
- Trends in diabetes dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- The leading diabetes deals by value since 2007
In Diabetes Partnering 2007-2012, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
Benefits
Diabetes Partnering 2007-2012 provides the reader with the following
key benefits:
- In-depth understanding of diabetes deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 500 actual diabetes deals entered into by the
world's biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in diabetes partnering
- 2.1. Introduction
- 2.2. Diabetes partnering over the years
- 2.3. Bigpharma diabetes dealmaking activity
- 2.4. Diabetes partnering by deal type
- 2.5. Diabetes partnering industry sector
- 2.6. Diabetes partnering by stage of development
- 2.7. Diabetes partnering by technology type
- 2.8. Disclosed financial deal terms for diabetes partnering
- 2.8.1 Diabetes headline values
- 2.8.2 Diabetes upfront payments
- 2.8.3 Diabetes milestone payments
- 2.8.4 Diabetes royalty rates
Chapter 3 - Leading diabetes deals
- 3.1. Introduction
- 3.2. Top diabetes deals by value
- 3.3. Top diabetes deals involving bigpharma
Chapter 4 - Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 - Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 - Deal type definitions
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Table of figures
- Figure 1: Diabetes partnering since 2007
- Figure 2: Bigpharma - top 50 - diabetes deals 2007 to 2011
- Figure 3: Bigpharma diabetes deal frequency - 2007 to 2011
- Figure 4: Diabetes partnering by deal type since 2007
- Figure 5: Diabetes partnering by industry sector since 2007
- Figure 6: Diabetes partnering by stage of development since 2007
- Figure 7: Diabetes partnering by technology type since 2007
- Figure 8: Diabetes deals with a headline value
- Figure 9: Diabetes deals with upfront payment values
- Figure 10: Diabetes deals with milestone payments
- Figure 11: Diabetes deals with royalty rates, %
- Figure 12: Top diabetes deals by value since 2007
- Figure 13: Top diabetes deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
Diabetes Partnering 2007-2012 published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 300 Pages and the price starts from US $ 1995.
